VHL and kidney cancer: Synthetic lethal effects of FTO and VHL, structural activation of VEGF and PDGF induced by VHL inactivation, and targeting of VEGF and PDGF to the downstream glutamine transporter SLC1A5 promote VHL deficiency-mediated metabolic reprogramming in kidney cancer cells and selectively affect the proliferation of VHL-deficient kidney cancer cells [91].